Nowadays, there have been several studies on the prognosis prediction of MM, such as gene expression inflammatory signature (Botta et al., 2016), EMC-92-gene signature (Kuiper et al., 2012), and genome-wide association studies (GWAS) of MM (Went et al., 2019), etc. Although these study all predict survival status in MM patients, we found that most of research either used CD138+ selected cells microarray or mixed samples from various time points. This evidence concerns the gene SDC1 and Miyoshi myopathy.